Last Price
303.99
Today's Change
+0.89 (0.29%)
Day's Change
300.79 - 305.00
Trading Volume
512,060
Overview
Market Cap
147 Billion
Shares Outstanding
484 Million
Avg Volume
687,333
Avg Price (50 Days)
305.09
Avg Price (200 Days)
289.05
PE Ratio
37.44
EPS
8.12
Earnings Announcement
12-Feb-2025
Previous Close
303.10
Open
302.12
Day's Range
300.79 - 305.0
Year Range
228.65 - 313.55
Trading Volume
512,060
Price Change Highlight
1 Day Change
0.29%
5 Day Change
-0.90%
1 Month Change
-0.14%
3 Month Change
5.19%
6 Month Change
7.86%
Ytd Change
5.44%
1 Year Change
13.34%
3 Year Change
-2.02%
5 Year Change
26.90%
10 Year Change
321.27%
Max Change
36658.16%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
2
CEO Morning Brief
Australian Economy Stuck in Slow Lane, Household Spending Drags
3
CEO Morning Brief
Australia's Top Diplomat Fears Firms Will Miss Southeast Asia's Boom
4
CEO Morning Brief
Australia Central Bank Governor Reiterates Rate Cuts Are Premature
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
